More IDO Issues: NewLink Drops Pancreatic Cancer Indication For Indoximod

NewLink has scrapped plans to explore its IDO inhibitor in pancreatic cancer – more bad news for a drug class that has suffered several setbacks recently.

Juggling
NewLink juggles too many indoximod options; drops pancreatic cancer program • Source: Shutterstock

NewLink Genetics Corp. has “deprioritized” pancreatic cancer and will not proceed with a planned Phase II study testing its lead product indoximod with AstraZeneca PLC's Imfinzi (durvalumab), the company said during its first-quarter earnings announcement.

This follows on from news last month that NewLink had halted the Phase III Indigo301 study of indoximod in combination...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer